Celecoxib was noninferior to diclofenac plus omeprazole for preventing gastroduodenal ulcer recurrence in high-risk patients with arthritis

May 2005
ACP Journal Club;May/Jun2005, Vol. 142 Issue 3, p76
Academic Journal
This article presents a study, which reports that celecoxib was noninferior to diclofenac plus omeprazole for preventing gastroduodenal ulcer recurrence in high-risk patients with arthritis. The study was conducted on 287 patients with arthritis and prior bleeding ulcer while on non-steroidal anti-inflammatory drugs (NSAID), who had endoscopy-confirmed ulcer healing and were currently negative for Helicobacter pylori infection, and who had anticipated regular use of NSAIDs. Results showed that celecoxib group did not differ from the diclofenac plus omeprazole group for the combined endpoint of recurrent bleeding ulcers and endoscopic ulcers.


Related Articles

  • What is the best NSAID regimen for arthritis patients with bleeding ulcer? Jackson, Eric A. // Journal of Family Practice;May2003, Vol. 52 Issue 5, p363 

    Among arthritis patients with a recent history of bleeding ulcer, cetecoxib was just as likely as diclofenac plus omeprazole to cause recurrent bleeding. The effectiveness of these two regimens in preventing recurrent bleeding compared with a general nonsteroidal anti-inflammatory drug (NSAID)...

  • Celecoxib shows similar rates of recurrent bleeding to diclofenac plus omeprazole.  // Formulary;Apr2003, Vol. 38 Issue 4, p194 

    Discusses the results of a study comparing the effectiveness of celecoxib, a nonsteroidal anti-inflammatory drug that is selective for cyclooxygenase and diclofenac plus omeprazole with respect to the prevention of recurrent ulcer bleeding in patients with arthritis. Probability of recurrent...

  • NSAID use in patients with prior MI.  // Neurology Alert;Jul2011 Pharmacology Watch, p1 

    The article reports on a study on the negative effect of the use of nonsteroidal anti-inflammatory drugs (NSAID) in patients who have experienced myocardial infarction (MI). Researchers from Denmark reviewed cases of around 84 thousand patients and saw a correlation with NSAID use and an...

  • EASING PAIN -- But Increasing Disease? Mann, Denise Lynn; Siegfried, Donna Rae // Arthritis Today;Sep/Oct2006, Vol. 20 Issue 5, p62 

    The article shows that although diclofenac (Voltaren) may ease pain and reduce swelling for osteoarthritis (OA), it may also make hip and knee OA progress, according to a study conducted by researchers in the Netherlands. Other nonsteroidal anti-inflammatory drugs such as aspirin and celecoxib...

  • Omeprazole: A Review of its Use in Helicobacter pylori Infection, Gastro-Oesophageal Reflux Disease and Peptic Ulcers Induced by Nonsteroidal Anti-Inflammatory Drugs. Langtry, H.D.; Wilde, M.I. // Drugs;Sep1998, Vol. 56 Issue 3, p447 

    Omeprazole is a well studied proton pump inhibitor that reduces gastric acid secretion. This review examines its use in Helicobacter pylori infection, gastro-oesophageal reflux disease (GORD) with or without oesophagitis and gastrointestinal damage caused by nonsteroidal anti-inflammatory drugs...

  • Accounting for the increase in NSAID expenditure: substitution or leakage? Barton, Garry R.; Avery, Anthony J.; Whynes, David K. // Cost Effectiveness & Resource Allocation;2006, Vol. 4, p1 

    Background: National Institute of Health and Clinical Excellence (NICE) guidance stated that a new form of non-steroidal anti-inflammatory drug (NSAID) (selective COX-2 inhibitors) should only be an option for arthritis patients at high risk of a gastro-intestinal (GI) event. Total expenditure...

  • Celecoxib most cost-effective choice in high-risk arthritis patients.  // PharmacoEconomics & Outcomes News;3/26/2005, Issue 474, p12 

    Discusses research being done on the cost effectiveness of using celecoxib for treating high-risk patients with arthritis in the U.S. Reference to a study by M. Schaefer, M. DeLattre et al, published in the January 2005 issue of the "Current Medical Research and Opinion" journal; Comparison of...

  • Helicobacter pylori and Peptic Ulcers in Rheumatoid Arthritis Patients Receiving Gold, Sulfasalazine, and Nonsteroidal Anti-Inflammatory Drugs. Taha, A. S.; Sturrock, R. D.; Russell, R. I. // American Journal of Gastroenterology;Dec1992, Vol. 87 Issue 12, p1732 

    The conflicting reports on gold and Heticobacter pylori could be related to the use of serological tests of unproven value in NSAID patients, and to the lack of the appropriate control groups. More important is the fact that the endoscopic consequences of the possible effect of gold on H. pylori...

  • Stomach Safety. Dunkin, Mary Anne; Ludlam, Kerry // Arthritis Today;May/Jun2006, Vol. 20 Issue 3, p72 

    Highlights the result of a study conducted on the safety of COX-2, a type of nonsteroidal anti-inflammatory drug (NSAID) to arthritis patients with stomach ulcer. Methodology of the study; NSAID included in the study; Conclusion of the study.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics